Results 121 to 130 of about 222,303 (308)
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le +5 more
wiley +1 more source
Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim +37 more
wiley +1 more source
A scoping review of quality prescribing indicators, rules and criteria for primary care
Medication‐related problems (MRPs) place a substantial burden on the healthcare system, contributing to hospital admissions and significant healthcare costs. Quality prescribing indicators (QPIs), rules and criteria serve to educate prescribers about high risk MRPs and to monitor prescribing behaviours. This study aims to summarize existing indicators,
James Nind +6 more
wiley +1 more source
Additive effect of polymorphisms in the β2‐adrenoceptor and
Tao Wang +5 more
openalex +1 more source
Abstract Aim Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model.
Seongmee Jeong +13 more
wiley +1 more source
External validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial
Diuretic resistance in worsening heart failure (HF) is associated with poorer outcomes and, although common, can be challenging to identify. The recently developed BAN‐ADHF score can potentially identify patients with worsening HF at risk of diuretic resistance.
Dominic M. Alfonso +10 more
wiley +1 more source
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source

